Allogeneic hematopoietic stem cell transplantation combined with imatinib for treatment of Philadelphia chromosome positive acute lymphoblastic leukemia / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 173-176, 2010.
Article
in Chinese
| WPRIM
| ID: wpr-328550
ABSTRACT
The study was purposed to explore the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) combined with Imatinib for treatment of Philadelphia chromosome positive acute lymphoblastic leukemia (Ph(+)ALL) patients. From 2007 to 2008, 3 patients with Ph(+)ALL were treated with allogeneic hematopoietic stem cell transplantation and Imatinib, and the follow-up ended at Oct 21(st) 2009. 1 patient received HSCT from matched sibling donor and 2 patients from haploidentical related donors. All 3 patients achieved complete remission before transplantation and were treated with Imatinib for distinct time at different periods before and/or after transplantation. The level of bcr/abl mRNA was monitored using real-time PCR. The results showed that all 3 patients achieved stable engraftments without severe transplantation related complications. The level of bcr/abl mRNA declined and achieved zero level finally. In conclusion, the allo-HSCT combined with Imatinib is an effective therapy regimen for Ph(+)ALL patients.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Piperazines
/
Pyrimidines
/
Therapeutics
/
Transplantation, Homologous
/
Benzamides
/
Treatment Outcome
/
Combined Modality Therapy
/
Hematopoietic Stem Cell Transplantation
/
Therapeutic Uses
/
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Limits:
Adolescent
/
Adult
/
Humans
/
Male
Language:
Chinese
Journal:
Journal of Experimental Hematology
Year:
2010
Type:
Article
Similar
MEDLINE
...
LILACS
LIS